Fertility and Sterility
Volume 85, Issue 1 , Pages 112-120 , January 2006

Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles

Received 19 March 2005 ,Revised 2 July 2005 ,Accepted 2 July 2005.

References 

  1. Al-Shawaf T , Grudzinskas JG . Prevention and treatment of ovarian hyperstimulation syndrome . Best Pract Res Clin Obstet Gynaecol . 2003;17:249–261
  2. Dahl Lyons CA , Wheeler CA , Frishman GN , Hackett RJ , Seifer DB , Haning RV . Early and late presentation of the ovarian hyperstimulation syndrome (two distinct entities with different risk factors) . Hum Reprod . 1994;9:792–799
  3. Mathur RS , Akande VA , Keay SD , Hunt LP , Jenkins JM . Distinction between early and late ovarian hyperstimulation syndrome . Fertil Steril . 2000;73:901–907
  4. Papanikolaou EG , Tournaye H , Verpoest W , Camus M , Vernaeve V , Van Steirteghem A , et al.   Early and late ovarian hyperstimulation syndrome (early pregnancy outcome and profile) . Hum Reprod . 2005;20:636–641
  5. Felberbaum RE , Ludwig M , Diedrich K . Are we on the verge of a new era in ART? . Hum Reprod . 1998;13:1778–1780
  6. Albano C , Felberbaum RE , Smitz J , Riethmuleer-Winzen H , Engel J , Diedrich K , et al.  European Cetrorelix Study Group   Ovarian stimulation with HMG (results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin) . Hum Reprod . 2000;15:526–531
  7. Born G , Mannaerts B  The European Orgalutran Study Group . Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient (results of a controlled, randomized, multicentre trial) . Hum Reprod . 2000;15:1490–1498
  8. Al-Inany H , Aboulghar M . GnRH antagonist in assisted reproduction (a Cochrane review) . Hum Reprod . 2002;18:874–885
  9. Aboulghar M . Prediction of ovarian hyperstimulation syndrome (OHSS). Estradiol level has an important role in the prediction of OHSS . Hum Reprod . 2003;18:1140–1141
  10. Orvieto R . Prediction of ovarian hyperstimulation syndrome. Challenging the estradiol mythos . Hum Reprod . 2003;18:665–667
  11. Navot D , Bergh PA , Laufer N . Ovarian hyperstimulation syndrome in novel reproductive technologies (prevention and treatment) . Fertil Steril . 1992;58:249–261
  12. Mathur R , Evbuomwan I , Jenkins J . Prevention and management of ovarian hyperstimulation syndrome . Curr Obstet Gynecol . 2002;12:111–116
  13. Delvigne A , Rozenberg S . Review of clinical course and treatment of ovarian hyperstimulation syndrome (OHSS) . Hum Reprod Update . 2003;9:1–20
  14. Ludwig M , Felberbaum RE , Devroey P , Albano C , Riethmuller-Winzen H , Schuler A , et al.   Significant reduction of the incidence of ovarian hyperstimulation syndrome (OHSS) by using the LHRH antagonist Cetrorelix (Cetrotide) in controlled ovarian stimulation for assisted reproduction . Arch Gynecol Obstet . 2000;264:29–32
  15. Pritts EA , Atwood AK . Luteal phase support in infertility treatment (a meta-analysis of the randomized trials) . Hum Reprod . 2002;17:2287–2299
  16. Haning RV , Austin CW , Carlson IH , Kusam DL , Shapiro SS , Zweibel WL . Plasma estradiol is superior to ultrasound and urinary estriol glucorinide as a predictor of ovarian hyperstimulation during induction of ovulation with menotropins . Fertil Steril . 1983;40:31–36
  17. Golan A , Ron-El R , Herman A , Soffer Y , Weinraub Z , Caspi E . Ovarian hyperstimulation syndrome (an update review) . Obstet Gynecol Surv . 1989;44:430–440
  18. Delvigne A , Dubois M , Battheu B , Bassil S , Meuleman C , De Sutter P , et al.   The ovarian hyperstimulation syndrome in in-vitro fertilization (a Belgian multicentric study II multiple discriminate analysis for risk prediction) . Hum Reprod . 1993;8:1361–1371
  19. D’Angelo A , Davies R , Salah E , Nix BA , Amso NN . Value of the serum estradiol level for preventing ovarian hyperstimulation syndrome (a retrospective case control study) . Fertil Steril . 2004;81:332–336
  20. Blankstein J , Shalev J , Saadon T , Kukia EE , Rabinovici J , Pariente C , et al.   Ovarian hyperstimulation syndrome (prediction by number and size of preovulatory ovarian follicles) . Fertil Steril . 1987;47:597–602
  21. Kaiser UB . The pathogenesis of the ovarian hyperstimulation syndrome . N Engl J Med . 2003;349:729–732
  22. Montanelli L , Delbaere A , Di Carlo C , Nappi C , Smits G , Vassart G , et al.   A mutation in the follicle-stimulating hormone receptor as a cause of familial spontaneous ovarian hyperstimulation syndrome . J Clin Endocrinol Metab . 2004;89:1255–1268
  23. Meirow D , Schenker JG , Rosler A . Ovarian hyperstimulation syndrome with low oestradiol in non-classical 17 alpha-hydroxylase, 17,20-lyase deficiency (what is the role of oestrogens?) . Hum Reprod . 1996;11:2119–2121
  24. Kol S . Luteolysis induced by a gonadotropin-releasing hormone agonist is the key to prevention of ovarian hyperstimulation syndrome . Fertil Steril . 2004;81:1–5
  25. Fauser BC , De Jong D , Olivennes F , Wramsby H , Tay C , Itskovitz-Eldor J , et al.   Endocrine profiles after triggering of final maturation with GnRH agonist after cotreatment with the GnRH antagonist ganirelix during ovarian hyperstimulation for in vitro fertilization . J Clin Endocrinol Metab . 2002;87:709–715
  26. Kolibianakis EM , Schultze-Mosgau A , Schroer A , van Steirteghem A , Devroey P , Diedrich K , et al.   A lower ongoing pregnancy rate can be expected when GnRH agonist is used for triggering final oocyte maturation instead of hCG, in patients undergoing IVF with GnRH antagonists . Hum Reprod . 2005;20:2887–2892
  27. Humaidan P , Bredkjaer HE , Bungum L , Bungum M , Grondahl ML , Westergaard L , et al.   GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles (a prospective randomized study) . Hum Reprod . 2005;20:1213–1220
  28. Tsirigotis M , Craft I . Ovarian hyperstimulation syndrome (OHSS) (how much do we really know about it?) . Eur J Obstet Gynecol . 1994;55:151–155
  29. Goldsman MP , Pedran A , Dominguez CE , Ciuffardi I , Levin E , Asch RH . Increased capillary permeability induced by human follicular fluid (a hypothesis for an ovarian origin of the hyperstimulation syndrome) . Fertil Steril . 1995;63:268–272
  30. McElhinney B , Ardill J , Caldwell C , Lloyd F , McClure N . Ovarian hyperstimulation syndrome and assisted reproductive technologies (why some and not others?) . Hum Reprod . 2002;17:1548–1553
  31. Papanikolaou EG , Kolibianakis EM , Devroey P . Emerging drugs in assisted reproduction . Exp Opin Emerg Drugs . 2005;10:425–440

PII: S0015-0282(05)03436-9

doi: 10.1016/j.fertnstert.2005.07.1292

Fertility and Sterility
Volume 85, Issue 1 , Pages 112-120 , January 2006

Article Tools

* Image Usage & Resolution